AstraZeneca announces EU approval of Imfinzi for muscle-invasive bladder cancer, showing significant survival benefits and addressing critical treatment needs.
AstraZeneca's report highlights Imfinzi's EU approval for muscle-invasive bladder cancer, showcasing significant efficacy from clinical trials. Key insights reveal its potential to redefine treatment standards.
Discover key findings from AstraZeneca's 6-K filing on Imfinzi, highlighting significant advancements in treating high-risk non-muscle-invasive bladder cancer through the POTOMAC trial.
Discover AstraZeneca's groundbreaking approval of Imfinzi for muscle-invasive bladder cancer, backed by clinical trials showing improved survival rates and reduced recurrence.